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ABSTRACT
PDIP46 (SKAR, POLDIP3) was discovered through its interaction with the p50
subunit of human DNA polymerase δ (Pol δ). Its functions in DNA replication are
unknown. PDIP46 associates with Pol δ in cell extracts both by immunochemical and
protein separation methods, as well as by ChIP analyses. PDIP46 also interacts with
PCNA via multiple copies of a novel PCNA binding motif, the APIMs (AlkB homologue-2
PCNA-Interacting Motif). Sites for both p50 and PCNA binding were mapped to the
N-terminal region containing the APIMs. Functional assays for the effects of PDIP46
on Pol δ activity on singly primed ssM13 DNA templates revealed that it is a novel and
potent activator of Pol δ. The effects of PDIP46 on Pol δ in primer extension, strand
displacement and synthesis through simple hairpin structures reveal a mechanism
where PDIP46 facilitates Pol δ4 synthesis through regions of secondary structure on
complex templates. In addition, evidence was obtained that PDIP46 is also capable of
exerting its effects by a direct interaction with Pol δ, independent of PCNA. Mutation
of the Pol δ and PCNA binding region resulted in a loss of PDIP46 functions. These
studies support the view that PDIP46 is a novel accessory protein for Pol δ that is
involved in cellular DNA replication. This raises the possibility that altered expression
of PDIP46 or its mutation may affect Pol δ functions in vivo, and thereby be a nexus
for altered genomic stability.

INTRODUCTION

on alterations of Pol δ and Pol ε that are associated with
cancer has emerged, as evidenced in studies of colorectal
and endometrial cancer [5, 6]. There remains a great deal
yet to be learned about mechanisms that could affect the
properties of the replicative polymerases and contribute to
cancer etiology.
There has been significant progress in the study of
human Pol δ and its regulation [7, 8]. The human Pol δ
holoenzyme (Pol δ4) is a heterotetramer consisting of
p125 (the catalytic subunit), p50, p68 [9], and a fourth
subunit, p12 [10], that is not present in S. cerevisiae Pol
δ [11]. Pol δ4 can be converted to the trimeric form (Pol
δ3) by the proteasomal destruction of p12 in response to
DNA damage [12, 13]. Pol δ3 is a physiologically active
enzyme that is engaged in DNA repair [14]. Pre-steady
state kinetic analyses of Pol δ4 and Pol δ3 have shown that
the p12 subunit exerts a profound influence on the kinetic
constants of Pol δ, such that Pol δ3 exhibits a decreased

Genomic stability in all organisms begins with
the process of DNA replication, which is performed by
replicative DNA polymerases endowed with exquisite
fidelity. An understanding of the properties and regulation
of the replicative DNA polymerases is therefore of crucial
significance in the context of the maintenance of genome
stability. Thus, the mechanisms by which the high fidelity
of DNA polymerases is achieved have been extensively
studied [1]. In human cells, there are two proofreading
DNA polymerases, Pol δ and Pol ε. Mutations that alter the
properties of Pol δ and Pol ε are of direct significance as a
potential of genomic instability [2, 3]. It is well recognized
that defects in the proofreading abilities of DNA
polymerases in a broad range of organisms play a crucial
role in increased mutation rate and genomic instability [4].
However, it is only recently that increasing information
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tendency for lesion bypass, increased stalling at template
lesions, and a greater proofreading ability through
alteration of the rate constants for the polymerization step
(kpol) and the translocation of the primer terminus from the
polymerase to the 3’ to 5’ exonuclease catalytic sites (kpol) [15, 16]. These studies have shown that the fidelity of
exo
Pol δ may be altered through interaction of the p12 subunit
with the catalytic core. A balance between Pol δ4 and Pol
δ3 appears to be required in vivo, since reduced expression
of p12 in cancer cells is associated with an increased
genomic instability and a poor prognosis for certain
lung cancers [17, 18]. The example of p12 also raises a
possibility for the existence of other protein interactors
of Pol δ that could affect its kinetic properties, including
processivity and fidelity.
Pol δ3 is also formed during the normal cell division
cycle at the G1/S transition, such that it is the predominant
form of Pol δ during S phase [19-21], consistent with its
having a role in DNA replication. The degradation of p12
is mediated by the ubiquitin ligase CRL4Cdt2 [19, 22] that
plays a major role in regulating the G1/S transition [2325]. We have reconstituted the human Okazaki fragment
processing system using both Pol δ3 and Pol δ4 [26,
27]. Both cooperate with Fen1 in removal of blocking
primers, so that both appear to be capable of participating
in Okazaki fragment processing but operate by different
mechanisms for the removal of blocking oligonucleotides
[8, 27].
Our laboratory has been interested in the search
for Pol δ interacting proteins, in order to identify novel
proteins that may be involved in regulating or augmenting
Pol δ functions. Screening by the yeast two-hybrid
system with the p50 subunit of Pol δ as the bait resulted
in identification of two Pol δ binding proteins, named
PDIP38 and PDIP46 [28]. PDIP46 was rediscovered as
SKAR (S6K1 Aly/REF-like target) [29, 30], a target of
ribosomal S6K1 kinase that is downstream of the mTOR
and PI3K signaling pathways that regulate cell growth
in response to nutritional and mitogenic signals [31].
SKAR has a RNA recognition motif (RRM), an abundant
nucleic acid binding domain [32], with homology to that
of the Aly/REF RNA binding protein that is involved in
posttranscriptional regulatory processes and mRNA export
[33]. Hyperphosphorylation and activation of S6K1 leads
to its binding to SKAR and the phosphorylation of SKAR;
this triggers the recruitment of SKAR/S6K1 to the exon
junction complex and increases the translational efficiency
of newly spliced mRNA [30]. Partial knockdowns of
S6K1 or SKAR result in reduction of cell size, and slowed
progression through S phase [29].
Other than the original description of the discovery
of PDIP46 (also known as POLDIP3) [28], no information
has emerged on the functional effects of PDIP46 on Pol δ.
Here we report the first detailed analysis of the effects of
PDIP46 on Pol δ function. Our studies show that PDIP46
is associated with Pol δ in a cellular context. Mapping
www.impactjournals.com/oncotarget

of the interaction sites of PDIP46 with p50 and PCNA
show that both sites are located in the N-terminal region,
and that PDIP46 interacts with PCNA via APIM motifs
(AlkB homologue 2 PCNA-Interacting Motif) [34]. We
performed a detailed examination of the effects of PDIP46
on human Pol δ activity using assays that assess its ability
for processive synthesis on long stretches of DNA, as
well as on model oligonucleotide templates. These studies
reveal that PDIP46 has a profound effect on the activity of
Pol δ, and support the hypothesis that PDIP46 has a role
in cellular DNA replication.

RESULTS
Association of PDIP46 with Pol δ
The only published information on the relationship
between PDIP46 and Pol δ was the demonstration of the
interaction between PDIP46 and the p50 subunit by the
yeast two-hybrid assay [28]. We first determined that
PDIP46 interacts with the intact Pol δ heterotetramer,
to ascertain that this interaction is not restricted to the
free p50 subunit used as the bait in the yeast two-hybrid
screen. This was established by the use of GST-PDIP46
pull-down assays, which demonstrated that all four
subunits of the Pol δ4 were pulled down (Figure 1A). This
interaction was also demonstrated in HeLa cell lysates by
immunoprecipitation with polyclonal antibodies against
PDIP46, where both the p50 and p125 subunits of Pol
δ were pulled down (Figure 1B). The latter result does
not necessarily show a direct interaction, since, as will be
shown below, PDIP46 also interacts with PCNA. However,
a more stringent immunochemical demonstration of the
association between PDIP46 was performed, by showing
that PDIP46 could be detected in the fractions from the
immunoaffinity chromatography of HeLa cell lysates on
immobilized p125 antibody; PCNA is not bound to this
column (Figure S1, Supplementary Data).
We also determined whether association of PDIP46
with Pol δ could be observed by the formation of higher
molecular weight complexes in cultured cell extracts.
Nuclear extracts of HEK 293 cells were chromatographed
on a Sepharose 6 gel filtration column (Figure 1C).
PDIP46 co-eluted in the same fractions as p125, in a
region where the ferritin marker (Mr 440,000) eluted.
(Two bands are found for PDIP46 by Western blotting;
these bands likely represent the full-length PDIP46
and its smaller alternatively spliced variant [29]). In
previous studies, purified recombinant Pol δ4 was found
to behave with a molecular weight (232,000-280,000)
consistent with its estimated molecular mass [35]. HEK
293 cell lysates were also subjected to nondenaturing gel
electrophoresis on gradient gels, under conditions where
the gels are run until limiting mobility is reached due to
6295
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pore size (Figure 1D). We had previously shown that Pol
δ in cultured cell extracts migrates at a position similar to
thyroglobulin (Mr 669,000). As seen in Figure 1D, both
the p125 subunit of Pol δ and PDIP46 co-migrate at a
position similar to thyroglobulin (Mr 669,000). Together,
these experiments support the idea that PDIP46 associates
with Pol δ in a cellular context.

whether it is bound to chromatin in association with
Pol δ and other replication proteins. We performed
chromatin immunoprecipitation of HeLa cells, using
an antibody against p125 [14], and immunoblotted for
PDIP46. PDIP46 was co-immunoprecipitated with p125
by ChIP analysis (Figure 2A). As a positive control, we
performed the same ChIP analysis and blotted for two
proteins associated with the replication fork, Mcm2 and
Ctf4 (Figure 2B). Mcm2 is a subunit of the Mcm2-7
helicase that together with Cdc45 and the GINS complex
form the CMG replicative helicase in yeast [36] and
humans [37,38]. Ctf4 (chromosome transmission fidelity
4) is important for sister chromatid cohesion and DNA

Association of PDIP46 with Pol δ on chromatin as
determined by ChIP analysis
An important step for establishing a role of
PDIP46 in DNA replication is the determination of

Figure 1: Association of PDIP46 with Pol δ by co-immunopreciptation, gel filtration, and native gradient gel
electrophoresis. A. PDIP46 interacts with the Pol δ4 holoenzyme. GST-PDIP46 (GST-p46) was used to pull-down purified Pol δ. The

pull-downs were western blotted for the p125, p68, p50, and p12 subunits of Pol δ. B. Co-immunoprecipitation of PDIP46 with Pol δ. HeLa
cell extracts were immunoprecipitated with antibodies against PDIP46, and western blotted for the p50 (left panel) and p125 subunits (right
panel) of Pol δ. C. Nuclear extracts of HEK 293 cells were chromatographed on a Superose 6 FPLC column as previously described [35].
Column fractions were western blotted for p125 and PDIP46. “BC” refers to the nuclear extract. Positions of molecular weight standards
are shown on the left. The arrows refer to the elution of protein standards (Mr: thyroglobulin, 669,000; ferritin, 440,000; aldolase, 158,000).
D. HEK 293 cell lysates were subjected to native (nondenaturing) gradient gel electrophoresis until limiting mobility was reached. Proteins
were transferred to nitrocellulose membranes and Western blotted for p125 and PDIP46 (Materials and Methods). The migration positions
of marker proteins (thyroglobulin, ferritin and catalase) and their respective native molecular weights are shown on the left.

www.impactjournals.com/oncotarget
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PDIP46 interacts with PCNA: identification
of PDIP46 as a novel member of the group of
proteins that interact with PCNA via APIM motifs

replication; it associates with the CMG helicase and
interacts with the replicative polymerases, most strongly
to Pol α, pointing to a role in replisome assembly [39,
40]. Taken together with data of Figure 1, these results
provide evidence that PDIP46 is associated with Pol δ at
the replication fork on chromatin.

We found that PDIP46 also interacts with PCNA.
Three GST-PDIP46 fusion constructs were used to
perform pull-down assays of PCNA. Only the full-length
PDIP46 and the N-terminal fragment (residues 1-141)
were able to pull-down PCNA (Figure 4A). PCNAbinding partners generally possess a PIP-box, a short
protein motif that binds to a hydrophobic pocket on PCNA
[41,42]. However, inspection of this N-terminal region (or
the entire PDIP46 sequence) did not reveal any sequences
corresponding to a canonical PIP-box. The N-terminal
sequence harbors five repeats of a short sequence (Figure

Mapping of the interaction domains between p50
and PDIP46
The region of p50 involved in PDIP46 interaction
was mapped using pull-down assays by the use of
GST-p50 deletion constructs to pull down his-tagged
PDIP46 (Figure 3A). This was shown to be between
residues 252-400 of p50. The interaction domain of
PDIP46 for binding to p50 was also mapped by the use
of GST-fusion deletion constructs of PDIP46 to pull down
his-p50 (Figure 3B). A diagram of the mutants that pulled
down his-p50 showed that the binding region on PDIP46
for p50 lies between residues 71-141 in the N-terminus
(Figure 3C, shaded region).

Figure 3: Mapping of the interaction sites between p50
and PDIP46. A. Mapping of the region of p50 that interacts

with PDIP46. GST-fusion constructs of p50 were used to pulldown his-PDIP46, and western blotted for PDIP46. Only the
deletion mutant containing residues 252-400 of p50 interacted
with PDIP46. B. Mapping of the PDIP46 region that interacts
with the p50 subunit of Pol δ. GST-PDIP46 deletions were used
for pull-down assays of his-p50, and western blotted for p50.
C. Diagrammatic summary of the data of panel B. Solid bars
show those deletion constructs that interacted with p50, and the
dashed lines show those that did not. The shaded area shows the
common region of the PDIP46 deletion mutants that interacted
with p50 (residues 71-141).

Figure 2: PDIP46 is associated with chromatin bound
Pol δ by ChIP analysis using antibody against p125.

ChIP analysis was performed with A549 cells as described in
“Materials and Methods”. A. The immunoprecipitates were
western blotted with antibodies against PDIP46 and the p125
subunit of Pol δ. IgG refers to the control immunoprecipitation
with non-immune serum. The bands marked “α” and “β” refer to
the full-length PDIP46 and its minor spliced variant, respectively.
B. ChIP analysis was performed as in (A) and western blotted for
MCM2 and Ctf4 which were used as positive controls.
www.impactjournals.com/oncotarget
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4B) which we identified as members of an alternative
PCNA binding motif [34], the APIM (AlkB homologue
2 PCNA-Interacting Motif). The APIM consists of five
residues with the consensus sequence [KR]-[FYW][LIVA]-[LIVA]-[KR] and was initially identified as
a novel PCNA binding motif in human oxidative
demethylase ABH2 (AlkB homologue 2), a DNA repair
enzyme [34]. Bioinformatics searches identified over
200 human proteins that contain APIMs; these include
many proteins that are involved in genomic maintenance
(DNA repair, DNA replication and cell cycle control)
[34]. However, functional PCNA binding by APIMs
has been demonstrated in only seven proteins to date ABH2, the transcription factor TFII-I, Topo IIα, Rad51B,
TFIIS-L [34], the nucleotide excision repair protein XPA

[43], and the F-box helicase, FBH1, that is involved in
homologous recombination [44]. The alignment of the
APIMs of PDIP46 with those of these seven proteins show
that they conform to the motif, with the exceptions of the
conservative replacements of phenylalanine with leucine
or isoleucine in three of the motifs (APIMs 2,3,5), and
all have additional variations in the aliphatic residues of
positions 3 or 4 (Figure 4B). A BLAST (tblastn) search
showed that the region (residues 50-130) containing all
five PDIP46 APIMs is almost completely conserved in
mammalian species, while the full-length sequence is
>90% conserved. PDIP46, while highly conserved in
higher vertebrates, does not appear to be present in lower
vertebrates [29].
In order to demonstrate that the APIMs are

Figure 4: PDIP46 interacts with PCNA, and does so via APIM motifs. A. Mapping of the PDIP46 domain that interacts with

PCNA. GST-PDIP46 deletion mutants were used to pull-down PCNA, and western blotted for PCNA. Only the GST-1-141 fusion protein
interacted with PCNA. B. The N-terminus of PDIP46 harbors 5 APIM motifs. The alignment shows the five APIM motifs of PDIP46,
together with those of the oxidative demethylase ABH2, the four APIMs of TFII-I, Topo IIα, Rad51B and TFIIS-L [34], FBH1 (F-box
helicase) [44] and XPA [43]. Residues in red show the conserved basic residues at positions 1 and 5, as well as the phenylalanine at position
2, while those in blue are the aliphatic residues at positions 3 and 4. All sequences shown are those of human proteins. C. Mutation of
the APIMs of PDIP46 leads to loss of PCNA binding. The conserved residues in positions 1, 2 and 5 of the APIM motifs were mutated to
alanines (PDIP46-5A). GST-PDIP46 and the GST-PDIP46-5A mutant were used in pull-down assays of PCNA. D. Mutation of the APIMs
of PDIP46 also leads to loss of p50 binding. GST-PDIP46 and the GST-PDIP46-5A mutant were used in pull-down assays of his-p50. E.
Domain map of PDIP46 showing the location of binding regions (boxed) for p50, PCNA (APIM motifs), RRM, and S6K1. The two S6K1
phosphorylation sites and the region deleted in a minor splice variant [29] are also shown.
www.impactjournals.com/oncotarget
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functionally responsible for the binding of PCNA by
PDIP46, we took the approach of mutating all five of
the motifs to generate the PDIP46-5A mutant to avoid
the complexity that might arise from the ability of the
individual motifs to bind PCNA. Residues at positions
1 (R/K), 2 (F/L/I) and 5 (R/K) in all five of the APIMs
(Figure 4B) were mutated to alanines. GST-PDIP46 and
GST-PDIP46-5A were used to pull-down PCNA (Figure
4C). PDIP46-5A exhibited near complete loss of PCNA
binding. These results eliminate the involvement of a
variant PIP-box elsewhere in PDIP46, noting that Topo IIα
[34] and FBH1 [34] possess both APIMs and PIP-boxes.
More detailed mutational analyses will be needed to
determine which of the five APIMs of PDIP46 are needed
for the interaction with PCNA. However, it is noted that
the first four APIMs are tightly clustered, with the spacing
being 10, 4, 2 and 32 amino acid residues between the
five APIMs so that there may be spatial or conformational
constraints on which of these interact with PCNA.
These data narrow down the region involved in
PCNA binding to the region containing the five APIMs
(residues 53 to 125). This closely overlaps the region
of PDIP46 for p50 binding (residues 71-141) that was
mapped by deletion mutagenesis (Figure 3C). The
possibility that mutation of the APIMs might also affect
p50 binding was considered. This was indeed found to
be the case, as the PDIP46-5A was found to have lost
the ability to bind to p50 (Figure 4D). This allows the
delimitation of the p50 binding region from residues
71-141 (Figure 3B, 3C) to residues 71-125. Thus, the
PDIP46-5A mutant is one that has lost interaction with
both PCNA and Pol δ.
The location of the APIMs, PCNA and Pol δ binding
regions are shown diagrammatically in the domain map
of PDIP46 (Figure 4E). Both the p50 and PCNA binding
regions of PDIP46 are located in the N-terminus, while
the binding region for S6K1, which is important for its
functions as the SKAR protein, are in the C-terminus
within the RRM. The separation of the interaction sites
for p50 and PCNA and the RRM are significant as they
are consistent with the idea that PDIP46/SKAR is a
bifunctional protein.

non-physiological, given the concentration levels needed,
and are not unexpected as they could be observed with
any other PCNA binding protein. In previous studies
of PDIP38, which also binds PCNA, we observed that
it inhibited the activity of Pol δ when assayed using
poly(dA)4000/oligo(dT)50 as the substrate [45]. These effects
occurred at micromolar levels of PDIP38, and are likely
due to competition with Pol δ for PCNA.
We re-assessed the effects of PDIP46 using singly
primed M13 DNA as the substrate (Figure 5A). The single
stranded M13 DNA is ca. 7 kb in size, and presents a more
complex template than the homopolymeric poly(A)4000
used in the poly(dA)/oligo(dT) assay, as it contains
regions of secondary structure. This assay has been used to
examine the ability of Pol δ/PCNA to perform processive
synthesis to the full-length products of ca. 7 kb [46], and
is regarded as an quasi-reconstitution assay that provides
an in vitro assessment of Pol δ capability in leading strand
synthesis in a processive manner [35, 38, 47, 48]. PCNA
is first loaded onto the primed M13 DNA by its clamp
loader, RFC, in the presence of RPA and ATP (Figure 5A).
Pol δ activity in this assay is dependent on the addition of
RPA single stranded binding protein [46].
PDIP46 was found to be a potent stimulator of
formation of the full-length 7 kb product by Pol δ4. The
formation of products at or near full-length extension of
the primer is dramatically increased by PDIP46 within a
concentration range from 0-150 nM (Figure 5B). Analysis
of product formation in the 7 kb range showed that the
reactions displayed saturation kinetics with increasing
concentration of PDIP46, and at the highest concentration
used, this amounted to a >10 fold increase in product
formation (Figure 5C). The data were fitted to a one site
binding hyperbola, giving an apparent KD of 34 ± 7.7 nM
(R2 = 0.98) (Figure 5C).
The time course of the formation of full-length M13
DNA in the presence of 20 nM PDIP46 is shown in Figure
5D. Even at 20 nM, PDIP46 dramatically accelerates
the formation of the full-length M13 products by Pol δ4
(Figure 5D, 5E).
With regard to our previous observations of an
inhibitory effect of PDIP46 in the poly(dA)/oligo(dT)
assay, we could also observe inhibition when we used
high concentrations of PDIP46 (Figure 5F, 5G). We reexamined the effects of PDIP46 on Pol δ activity in
the poly(dA)/oligo(dT) assay using a lower range of
concentrations, but were unable to detect any stimulation
of Pol δ activity (data not shown). It is noted that the
template in this case is a homopolymer, and lacks any
sequence complexity.
The effects of increasing Pol δ4 levels in the absence
and presence of a fixed PDIP46 concentration (100 nM)
were examined (Figure S3A, S3B, Supplementary Data).
Product formation was quantitated for the major products
in the 3-7 kb range as well as for the 7 kb range (Figure
S3C,D, Supplementary Data). In both cases, apparent

PDIP46 is a potent activator of Pol δ4 in primer
extension assays which require highly processive
synthesis
We had examined the effects of PDIP46 on Pol δ
using poly(dA)4000/oligo(dT)50 as the substrate. This assay
is commonly used for the assay of Pol δ activity. In this
assay Pol δ was inhibited with half maximal inhibition at
about 1 µM of PDIP46. The inhibition could be relieved
by increasing the concentration of PCNA (Figure S2,
Supplementary Data), indicating a competition between
Pol δ and PDIP46 for PCNA. Such effects are likely to be
www.impactjournals.com/oncotarget
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Figure 5: PDIP46 stimulates product formation by Pol δ4 in the M13 assay. A. Diagram of the M13 assay of Pol δ activity.

Singly primed M13 ssDNA (left) is loaded with PCNA with RFC, and RPA single stranded DNA binding protein (center); Pol δ4 and
[α-32P]-dATP is added to extend the primer up to the full-length product (right). B. Effects of increasing concentrations of PDIP46 on Pol δ4
activity. Pol δ4 concentration was 5 nM, M13 ssDNA was 2.5 nM, and PCNA was 6 nM (Materials and Methods). Reactions were incubated
at 37° C for 25 min. Products were analyzed by electrophoresis on 1.2% alkaline agarose gels and were visualized by phosphorimaging.
Lane M shows the migration of the markers. The bracket on the top left indicates the region that was used for quantitation of full-length 7 kb
products. The asterisks show bands where pausing of the reactions occurred. C. Full-length product formation for panel B was quantified,
and plotted as relative product formation against PDIP46 concentration. The data were fitted to a one site binding hyperbola using Prism
software, and gave an apparent KD of 34 ± 7.7 nM (R2 = 0.98). D. Time dependence of product formation by Pol δ4 in the M13 assay in the
presence of PDIP46. Pol δ4 (10 nM) was assayed on singly primed M13 in the absence (left panel) and presence (right panel) of PDIP46
(20 nM); the reactions were analyzed after 5, 10, 15, 20, 25 and 30 min. E. Product formation of the full-length products in panel D was
quantified, and plotted as relative product formation against time. Data in the absence of PDIP46 are shown as circles, and those in the
presence of 20 nM PDIP46 are shown as squares. F. The effects of higher concentrations (0-400 nM) of PDIP46 on Pol δ (20 nM) assayed
on the M13 substrate. Reaction times were 15 min. G. The full-length products for panel F were quantified and plotted against PDIP46
concentration.
www.impactjournals.com/oncotarget
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saturation of the product formation was observed, that
was increased in the presence of PDIP46. This result is
consistent with the possibility that there may be an effect
on the intrinsic activity of Pol δ.
Overall, our findings show that PDIP46 exhibits a
remarkable ability to stimulate product formation by Pol
δ4, by as much as an order of magnitude. While human
Pol δ4 is capable of processive synthesis on M13 ssDNA
templates in the presence of PCNA, it has been reported
to dissociate frequently [38,49], and differs from yeast Pol
δ which is highly processive [48], i.e., its processivity is
not such that it can synthesize the entire M13 DNA in a
single binding event. This is evident in that M13 DNA
possesses regions of secondary structure that give rise
to observable pause sites (Figure 5B, asterisks). These
pause sites represent the slowing of Pol δ synthesis
through these regions. Facilitation of Pol δ synthesis
through these regions could contribute to an increase in
apparent processivity of Pol δ. The stimulation of product
formation by PDIP46 could be caused by contributions
of several mechanisms that include direct activation of
Pol δ, an actual effect on processivity, or the ability to
facilitate Pol δ elongation through regions of secondary
structure. Further complexities involved in understanding
how PDIP46 affects Pol δ activity arise because it binds to
both Pol δ and with PCNA and has the potential to act as a
bridge to stabilize their interaction on DNA.

substrates, identical to those we had previously utilized for
the reconstitution of human Okazaki fragment processing
[26, 27]. The component reactions include primer
extension as well as strand displacement reactions. The
oligonucleotide substrate consisted of a 5’ end-labeled
34mer annealed to a 70mer template (Figure 6A). We also
tested the PDIP46-5A and PDIP46-∆RRM mutants to
establish that the functional effects resided in the binding
regions for Pol δ and PCNA. The PDIP46-∆RRM mutant
is one in which the RRM domain (residues 280-351) in the
C-terminus were deleted. Here, we were concerned that

PDIP46 stimulates primer extension by Pol δ on
model oligonucleotide substrates
In order to further explore the effects of PDIP46 on
Pol δ4 activity and to gain insights on its potential mode
of action, we examined its effects using oligonucleotide
Figure 6: PDIP46 and PDIP46-∆RRM but not
PDIP46-5A stimulate primer extension by Pol δ4 on
oligonucleotide substrates in the absence of PCNA. A.

Oligonucleotide substrate for primer extension. A 5’-[32P]endlabeled 34mer primer was annealed to a 70mer template. The
asterisk denotes the labeling. B. Effects of PDIP46 and PDIP465A (50 nM) on primer extension by Pol δ4 in the absence of
PCNA. The concentration of reactants were DNA substrate
(100 nM), Pol δ4 or Pol δ3 (5 nM), PDIP46, PDIP46-∆RRM
or PDIP46-5A (50 nM). The reactions were performed for
times ranging from 0-10 min. Reaction products were resolved
by electrophoresis on sequencing gels and visualized by
phosphorimaging (Materials and Methods.). C. The full-length
70mer primer extension products for panel B were quantified
and plotted (as % of primer converted to 70mer) against time.
Data for Pol δ4 in the absence of PDIP46 is shown as solid
circles, with PDIP46 as solid squares, with PDIP46-∆RRM as
shaded diamonds and with PDIP46-5A as shaded triangles. D.
Effects of PDIP46 and PDIP46-5A on Pol δ3 activity in the
absence of PCNA. Reactions were performed as described in B.
The vertical bracket on the gel show a region of primer extension
that is increased in the presence of PDIP46.
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the RRM motif, which binds RNA, is also able to bind
ssDNA, and could have a potential effect on Pol δ.
The effects of PDIP46 on Pol δ4 were first
examined in the absence of PCNA. Pol δ4 produced
a ladder of products, as expected from a distributive
mode of synthesis. PDIP46 strongly increased formation
of full-length 70mer extension products (Figure 6B,
6C). Removal of the RRM did not affect the ability of
PDIP46 to stimulate Pol δ4 activity. Mutation of the
APIMs abolished the effects of PDIP46, showing that the
functional effects are due to Pol δ interaction. The ability
of PDIP46 to activate Pol δ4 in the absence of PCNA
provides clear evidence that there is a direct effect on Pol δ
activity, independent of the presence of PCNA. While the
action of Pol δ in the context of its functions in replication
require its interaction with PCNA, these findings are
highly significant in the context of understanding the
mechanism of the effects of PDIP46 on Pol δ. This is
because the properties of Pol δ are dictated by a complex
kinetic scheme [7, 16] shared by other replicative DNA
polymerases [1, 50-52]. Alterations in these kinetic
constants can not only alter steady state activity, but also
fidelity and processivity [50].
We examined the effects of PDIP46 on Pol δ3
(Figure 6D). In the absence of PCNA, Pol δ3 activity is
lower than that of Pol δ4, and is only weakly stimulated
by PDIP46. This effect is abolished in the PDIP46-5A
mutant, confirming that the effects are due to PDIP46.
The effects of PDIP46 on Pol δ4 in the presence of
PCNA were examined. For these experiments the same
substrate was used, but the biotinylated template ends
were blocked with streptavidin (Figure 7A) and PCNA
was loaded with RFC [27]. Primer extension by Pol δ4 was
markedly stimulated by PCNA alone, as expected, with
the shift to processive synthesis seen by the appearance
of the full-length extension products even at the earliest
time points (Figure 7B, left panel). PDIP46 nevertheless
further stimulated Pol δ4 as shown by quantitation of the
70mer full-length products. As with the primer extension
experiments in the absence of PCNA (Figure 6B), no
effects of the deletion of the RRM domain were seen,
while the PDIP46-5A lost the ability to stimulate Pol δ4
(Figure 7B, 7C).
The smaller stimulation by PDIP46 in the presence
of PCNA compared to those in the absence of PCNA may
be due to the overriding effects of PCNA. (We have also
used the unblocked template, and have obtained essentially
similar results, consistent to our previous observations
[27]. These findings also eliminate the possibility that
PDIP46 affects the loading of PCNA by RFC.)

with a 5’-[32P]end-labeled 34mer primer and a 31mer
blocking sequence (Figure 8A) [27]. On this substrate,
Pol δ rapidly extends the 34mer primer to fill in the 5nt
gap to form a 39mer and then stalls on encountering the
5’ end of the blocking oligonucleotide. Further primer
extension then requires displacement of the blocking
oligonucleotide, which takes place at a slower rate, and

Figure 7: Effects of PDIP46, PDIP46-∆RRM
and PDIP46-5A on primer extension by Pol δ on
oligonucleotide substrates in the presence of PCNA. A.

Oligonucleotide substrate for primer extension. A 5’-[32P]endlabeled 34mer primer was annealed to a 70mer template, and
was then blocked with streptavidin (shaded sphere). PCNA was
then loaded onto the substrate with RFC. B. Effects of PDIP46
and PDIP46-5A (50 nM) on primer extension by Pol δ4 in the
presence of PCNA. The concentrations of reactants were DNA
(50 nM), Pol δ4 (10 nM), PCNA (50 nM), PDIP46 or its mutants
(50 nM). Conditions used were as described in Materials and
Methods. The reactions were performed for times ranging from
0-10 min. Reaction products were resolved by electrophoresis
on sequencing gels and visualized by phosphorimaging. C.
Amounts of 70mer formed in panel B were determined and
plotted against time. Data for Pol δ4 in the absence of PDIP46
is shown as solid circles, with PDIP46 as solid squares, with
PDIP46-∆RRM as shaded diamonds and with the PDIP46-5A
mutant as shaded triangles.

Effects of PDIP46 on strand displacement by Pol
δ on a model oligonucleotide substrate
The effects of PDIP46 on strand displacement by Pol
δ4 were examined using a 70mer oligonucleotide template
www.impactjournals.com/oncotarget
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provides an assay for strand displacement. Negligible
strand displacement occurred in the absence of PCNA
(Figure 8B), consistent with our previous observations
that strand displacement by Pol δ4 is dependent on the
presence of PCNA [27]. PCNA markedly stimulated
strand displacement, giving rise to a ladder of intermediate
products and the formation of the 70mer (Figure 8C, left
panel). Quantitation of the 70mer strand displacement

product or of the combined strand displacement products
between the 40-70mer (Figure 8D, 8E) shows quite clearly
that strand displacement is stimulated by PDIP46. These
effects were lost when the PDIP46-5A was used. Pol δ3
itself has no significant strand displacement activity [27]
and was not significantly affected by PDIP46 in this assay
(data not shown).

Figure 8: PDIP46 stimulates strand displacement by Pol δ4. A. Oligonucleotide substrate for primer strand displacement assays.

A 5’-[32P]end labeled 34mer primer was annealed to a 70mer template as in Figure 6, together with a downstream blocking 31mer to
leave a 5nt gap. The asterisk denotes the labeling. The concentration of reactants were DNA template (100 nM), Pol δ4 (5 nM), PDIP46
or PDIP46-5A (50 nM), and PCNA (100 nM) when added. Reactions were performed for the indicated times. B. Effects of PDIP46 and
PDIP46-5A (50 nM) on strand displacement by Pol δ4 in the absence of PCNA. Reaction products were visualized by phosphorimaging.
C. Effects of PDIP46 and PDIP46-5A on strand displacement by Pol δ4 in the presence of PCNA. Reaction products were visualized by
phosphorimaging. D. The 70mer full-length primer extension products for C, reflecting complete strand displacement of the blocking
31mer oligonucleotide, were quantified and plotted as 70mer formed as % of primer against time. Data points in the absence of PDIP46 are
shown as solid circles, with PDIP46 as solid squares, and with PDIP46-5A as shaded triangles. E. The overall strand displacement products
as reflected by primer extension products from the 40mer-70mer (indicated by the bracket in C) were quantified and plotted against time.
Data points were labeled as for panel D.
www.impactjournals.com/oncotarget
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PDIP46 enhances the ability of Pol δ4 to
synthesize through a model oligonucleotide
substrate with a hairpin secondary structure

product formation by Pol δ3 was very minimal, about 2%
that of Pol δ4. Nevertheless, PDIP46 increased this by ca.
4-fold. An increase in activity with the PDIP46-∆RRM
was observed but this may not be significant due to the
low levels of activity.
It is noted that the model of the reactions
(Figure 9A) illustrates that passage through the stem
region is a reaction that bears resemblance to strand
displacement. Comparison of the rates of synthesis in
strand displacement (Figure 8D), in which the Pol δ4
concentration was half that used in Figure 9E, shows that
the rates of synthesis are roughly comparable in terms of
full length products formed.
These experiments suggest a hypothesis whereby
the ability of PDIP46 to stimulate Pol δ4 synthesis of
the full length M13 substrate can be explained by the
cumulative effect of the facilitation of Pol δ4 synthesis
through multiple regions of secondary structures. This is
presented in more detail in the Discussion.

The ability of PDIP46 to stimulate strand
displacement activity by Pol δ4 provides insights into its
potential mode of action when considering the effects on
Pol δ4 function in the context of complex templates such
as M13 ssDNA template, viz., that PDIP46 might facilitate
synthesis by Pol δ through regions of secondary structure
that involve simple stem-loop or hairpin structures. The
model substrate consisted of a 64mer template, with a
3’-biotin tag (Figure 9A, “I”). The 5’-end of the template
contained a complementary region of 16 nt to form a
short stem, and followed by 8 non-complementary nts
to form a loop. To this was annealed a 5’-[32P] labeled
primer, leaving a gap of 5 nt. Streptavidin was used to
cap the 3’-biotinylated template end to prevent PCNA
from sliding off after it was loaded with RFC [27]. The
expected progress of the reaction is shown in a stepwise
manner in Figure 9A, to illuminate the analogy with
the strand displacement reactions of Pol δ [27]. Pol δ is
expected to rapidly extend the primer to fill in the gap
until 5’ end of the stem is reached (Figure 9A, “II”). The
further process of synthesis through the stem is analogous
to strand displacement, noticing that in the process a flap
is formed, as the stem region is shortened, giving rise to a
familiar stem-loop arrangement (Figure 9A, “III”). Once
Pol δ has traversed the stem region (Figure 9A, “IV”) the
hairpin is opened and Pol δ is expected to rapidly complete
synthesis to the end of the template (Figure 9A, “V”).
The results of the experiment show that Pol δ4
performs synthesis through the hairpin as predicted as can
be seen from the gel (Figure 9B). The gap filling is rapid,
so that the 19mer is largely converted to the 24mer within
the first time point. This is followed by the formation of a
ladder of products arising from a slower progression in a
process of strand displacement, and a more rapid reaction
once the stem region is passed as seen by the absence of
intermediates. Quantitation of the phosphorimage showed
that PDIP46 (50 nM) readily stimulated the rate of Pol δ
synthesis through the hairpin, by a factor of ca. 3.6 fold
(Figure 9C). [This is also evident from the disappearance
of the 24mer in the presence of PDIP46 (Figure 9B)]. The
effects of higher concentrations of PDIP46 were examined.
Here, as with the M13 substrate, PDIP46 was inhibitory at
high concentrations (Figure S4, Supplementary Data).
We examined the behavior of the PDIP46-∆RRM
mutant (Figures 9D, 9E). The PDIP46 stimulation of Pol
δ4 on the hairpin substrate was found to be independent of
the RRM motif. The ability of PDIP46 to stimulate strand
displacement and synthesis through hairpin structures
may underlie its effects on Pol δ4 synthesis in the M13
assay. We also performed a similar experiment with Pol
δ3 (Figure S5, Supplementary Data). The rate of 64mer
www.impactjournals.com/oncotarget

DISCUSSION
Characterization of PDIP46 interactions with Pol
δ and PCNA
The studies reported here provide the first detailed
examination of the interaction of PDIP46 with Pol δ
and PCNA and of its functional effects on Pol δ activity.
We established that PDIP46 is associated with Pol δ in
cellular extracts by classical protein separation and
immunochemical procedures (Figure 1) and that PDIP46
is associated with Pol δ by ChIP analysis with anti-p125
antibody, providing direct evidence that PDIP46 is
chromatin bound in the spatial proximity of Pol δ (Figure
2). These observations support the hypothesis that PDIP46
interaction with Pol δ is functionally meaningful in terms
of a role in DNA replication.
Detailed analysis of the interaction sites of PDIP46
for the p50 subunit of Pol δ and PCNA, established that
these located in the N-terminus (Figures 3, 4). PDIP46
was shown to be a novel member of a group of proteins
that interact with PCNA via APIM motifs [34]. Studies
using mutants of PCNA in the PIP-box domain and FRET
analyses have provided some evidence that the APIMs
may bind to the same hydrophobic pocket of PCNA as the
PIP-box [53], so that competition between PCNA binding
proteins that utilize a PIP-box may occur. However, the
biochemical or structural basis of the interaction of the
APIM motif with PCNA has yet to be determined. Further
studies are required to determine which of the PDIP46
APIM motifs are functionally involved in PCNA binding.
Mutation of all five APIMs leads to loss of both
p50 and PCNA binding. This established that the
functional effects of PDIP46 are dependent on p50 and
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Oncotarget

Figure 9: PDIP46 stimulates primer extension by Pol δ4 through a template with a hairpin. A Diagram of the substrate and

expected progression through the stem loop structure. For details see text. B. Pol δ4 (15 nM) was reacted for the indicated times with the
substrate (50 nM) in the absence and presence of PDIP46 (50 nM) after the loading of PCNA with RFC (Experimental Procedures). The
products were analyzed by 8M urea denaturing polyacrylamide gel electrophoresis and visualized by phosphorimaging. The arrowheads
indicate the positions of the primer (19nt), the position at the point of primer extension to the 5’-end of the template at the start of the hairpin
(24nt), and the full-length product (64nt). C. The amounts of 64mer representing synthesis through the hairpin for the phosphorimage in B
were quantified. Data are plotted as percentage of primer converted in the absence (solid circles) and presence (solid squares) of PDIP46. D.
The RRM region is not required for PDIP46 stimulation of Pol δ4. The effects of PDIP46 and the PDIP46-∆RRM mutant were examined.
The concentrations of the reactants were DNA (50 nM), Pol δ4 (10 nM), and PDIP46 or PDIP46-∆RRM (50 nM). E. Formation of the
64mer for panel D was quantified and plotted against time. Data for the control are shown as solid circles, for PDIP46 as solid squares, and
for PDIP46-∆RRM as solid diamonds.
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PCNA binding (Figure 4). Studies of the PDIP46-∆RRM
mutant show that the effects of PDIP46 on Pol δ4 are
independent of the RRM domain associated with the
functions of PDIP46 studied as the SKAR protein (Figures
6, 7). This demonstration provides a physical basis for the
bifunctional nature of PDIP46. Further work is needed to
determine the exact location of the p50 binding region of
PDIP46, in order for studies that might lead to generation
of mutations that have lost either PCNA or p50 binding.

much greater than those observed with the oligonucleotide
substrate containing a single hairpin. This idea also
explains why no significant stimulation was observed
on the homopolymeric poly(dA) template. In addition, it
is an attractive possibility that an interaction of PDIP46
with both PCNA and Pol δ4 could stabilize the Pol δ4/
PCNA complex and contribute to the effects of PDIP46
on processive synthesis as well as stimulation of Pol δ4
synthesis through complex templates. Further studies are
needed to clarify this issue, and await the development of
mutants that can selectively affect PCNA and p50 binding
to PDIP46.
It should be noted that while PDIP46 potently
stimulates Pol δ4 synthesis on the M13 template, this
should also be viewed in the context that even small
secondary structures can considerably slow down Pol δ4
synthesis. This also serves as a reminder that analyses of
Pol δ4 activity on homopolymeric templates do not reflect
those encountered on more complex templates.
The extension of our findings using these substrates
to DNA replication in human cells is that PDIP46 could
enhance the rate of polymerization by Pol δ4 as well as its
ability for bypass synthesis through secondary structures.
While it is well accepted that DNA polymerases are
impeded by secondary structures, there are few studies
of the human DNA polymerases on such templates.
Regions of stalling of Pol δ4 have been analyzed in the
human FRA16D and FRA3B CSFs (common fragile site)
[54, 55], sites of major chromosomal instability [56, 57].
The majority of the pause sites involve relatively small
simple hairpins, such as the one used in this study, with
loop regions of less than 10 nts and variable stem lengths
[54, 55]. The human genome contains significant amounts
of sequences that are the recognition sites for replication
initiation, transcription, telomeres, amongst others, that
pose challenges for human replicative polymerases. These
DNA sequences form secondary structures, some as short
hairpins and others as complex non-B DNA structures.
Replication stalling caused by these sequences is now
recognized as a major source of genomic instability
that leads to cell death (aging) or transformation
(tumorigenesis). These secondary structures can pose
impediments to Pol δ, as well as lead to increased error
rates [54, 55, 58-60].

Insights from studies of PDIP46 activity using
model substrates: a working hypothesis for the
mechanism of stimulation of Pol δ4 activity on
singly primed ssM13 DNA via PDIP46 facilitation
of bypass synthesis through secondary structures
The major and critical outcome of our studies is the
discovery that PDIP46 has a profound effect on Pol δ4
activity, which is evident when its effects are examined
in assays of primer elongation on singly primed ssM13
DNA. PDIP46 causes an elevation (ca.10-fold) of Pol δ4
activity, which is manifested at low concentrations with an
apparent KD of ca 34 nM (Figure 5).
The experiments using oligonucleotide substrates
have provided significant insights into the potential
mechanisms that underlie the ability of PDIP46 to
stimulate synthesis of full-length products in the
M13 assay by Pol δ. A summary of the results of the
oligonucleotide experiments is shown diagrammatically in
Figure 10. The ability of PDIP46 to affect primer extension
in the absence of PCNA unequivocally shows that this
is mediated via a direct interaction with Pol δ4 (Figure
10A, 10B). In the presence of PCNA, Pol δ4 synthesis is
greatly stimulated, but is nevertheless further stimulated
by PDIP46 (Figure 10C, 10D). In this instance, we cannot
distinguish whether this stimulation is solely due to an
effect on Pol δ, or whether it also involves its ability to
bind PCNA, as the PDIP46-5A mutation abrogates both
p50 and PCNA binding. The detailed mechanism(s) for
the ability of PDIP46 to directly stimulate Pol δ remain
to be determined by more intensive kinetic studies, such
as pre-steady state kinetic analysis, since this could define
changes in Pol δ at the catalytic level.
PDIP46 significantly stimulates the ability of Pol
δ4 for bypass synthesis through a model hairpin template
(Figure 10E, 10F). This provides an explanation of why
PDIP46 so strongly facilitates synthesis on the more
complex M13 ssDNA template (Fig. 10G, 10H). The M13
ssDNA template contains multiple secondary structures,
each of which could lead to a slowing of Pol δ4, as
well as a potential for causing increased dissociation of
Pol δ4. Thus, even modest effects of PDIP46 would be
cumulative in the M13 template. The effects of PDIP46,
observed over the period required for completion of the
synthesis of the 7 kb full-length M13 DNA, would be
www.impactjournals.com/oncotarget

Potential cellular roles of PDIP46 as a modulator
of Pol δ4 functions at the replication fork
Our findings have shown that PDIP46 has a
profound effect on Pol δ4, while having lesser effects on
Pol δ3, particularly in the context of its effect on strand
displacement and bypass of hairpin structures. Thus, this
establishes a strong basis for a potential role of PDIP46
in replication, specifically in facilitating synthesis through
regions of secondary structures. Obviously, there are
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a large number of cellular helicases that also could be
involved in resolving complex structures. Nevertheless,
the stimulation of Pol δ4 through secondary structures
provides another model for an accessory protein that
cumulatively could speed up Pol δ4 synthesis over long
stretches of DNA. Further studies of the effects of PDIP46
through more complex secondary structures such as
trinucleotide repeats would add to our understanding of
its role. Because PDIP46 appears to function by increasing
the processivity of Pol δ4, it could act as a partner of
Pol δ/PCNA at the replication fork as an “auxiliary” or
“accessory” protein. While further research is needed to
establish whether PDIP46 is a true accessory protein, and
to establish its contributions to DNA replication in vivo,

our present studies provide a reasonable foundation and
rationale for explorations of this possibility. It is relevant
that the in vitro activity of Pol δ is much slower than the
estimated rate of in vivo synthesis, so that its function
within the replisome might require additional protein
factors. Assays of steady state rates of synthesis by Pol δ4
in standard assays give rates of ca. 1 to 3nts/sec [38, 47],
while the in vivo rate of synthesis in human cells has been
estimated to be in the order of 30nts/sec in HeLa cells,
as determined by BrdU labeling and DNA fiber analysis
[61]. In yeast reconstituted replication systems, the rate
of DNA synthesis is also about 10 fold lower than that in
vivo [36, 62, 63].
There have been extensive studies in yeast by

Figure 10: Diagrammatic summary of the effects of PDIP46 on Pol δ4 activity. (A., B.) PDIP46 stimulates Pol δ4 in the
absence of PCNA, revealing a direct effect on Pol δ4. (C., D.) Pol δ4 synthesis in the presence of PCNA. Pol δ4 is strongly stimulated by
PCNA alone, due to its conversion to a processive mode of synthesis, but this is further stimulated by PDIP46. (E., F.) PDIP46 stimulates
PCNA-enabled synthesis through a hairpin secondary structure. (This is similar to effects in strand displacement, which are omitted). It is
proposed that there is an additive effect of PDIP46 on Pol δ4 synthesis over that observed with oligonucleotides with a single secondary
structure; this is illustrated in G. and H., to show the additive nature of the facilitation of synthesis when multiple stem-loop/hairpin
structures are present. This provides a working hypothesis for the potent stimulation of Pol δ4 synthesis of full-length products in the M13
assay by PDIP46. The increases in product formation are qualitatively represented by increases in weight of the dotted arrows for all panels.
The direct effects of PDIP46 on Pol δ that indicate alteration in Pol δ function are shown by shadowing of the icons for Pol δ4 (B, D, F).
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several approaches that support the paradigm for a
division of labor for Pol δ and Pol ε at the lagging and
leading strands, respectively [36, 64-66], although a
very recent study supports a major role for Pol δ in both
leading and lagging strands [67]. Less direct experimental
evidence is available in mammalian systems as to the
designation of the roles of Pol δ and Pol ε. Subcellular
localization studies of Pol δ and Pol ε in human cells
during cell cycle progression as well as ChIP analyses
have provided evidence that Pol δ and Pol ε may operate
independently during S phase [68-70]. Our findings that
PDIP46 accelerates Pol δ4 synthesis is consistent with
a function as an accessory protein that allows Pol δ4 to
participate in leading strand synthesis, together with Pol ε.
Our current findings have highlighted the connection
between strand displacement and the synthesis through the
stem portion of stem-loop secondary structures; the lack of
strand displacement activity by Pol δ3 also means that it
is less able than Pol δ4 to negotiate stem-loop structures.
Thus, we envisage that Pol δ4, with the assistance of
PDIP46 may also be utilized in lagging strand synthesis to
deal with such structures by switching with Pol δ3. This
is consistent with findings that both Pol δ4 and Pol δ3
are proficient in Okazaki fragment processing with Fen1
and DNA ligase I [27]. Our studies would expand the
latest model of the replication fork in higher eukaryotes
which has Pol δ at both leading and lagging strands [71]
to accommodate two forms of Pol δ and the participation
of PDIP46.

[74] and DNA damage response genes including ATR [75]
as well as replication proteins [76].
Another important question that is raised is the
potential role PDIP46 has on genomic stability, bearing
in mind that PDIP46 has direct effects on Pol δ. As noted
previously, these could lead to alterations of the kinetic
constants of Pol δ that could affect its intrinsic processivity
as well as fidelity, thereby raising the issue of PDIP46
depletion or mutation as a potential source of genomic
instability. While the study of PDIP46/SKAR functions
are still at an early stage, it is nevertheless apparent that
even within its currently known properties that it has
the potential to play a role in the cancer process, either
in terms of genomic stability directly by affecting DNA
replication at the core level of synthesis and fidelity, or
in terms of growth regulation and its role in transducing
expression of replication and signaling proteins or antineoplastic factors as described above. Highly pertinent
to the issue of PDIP46/SKAR as a protein that may
have potential as a target for oncogenesis are the recent
studies that have identified POLDIP3 as one of a group
of genes with altered copy number and expression in
metastatic site-derived aggressive cells that exhibited
high tumorigenic potential; moreover, reduced POLDIP3
expression was correlated with decreased overall and
relapse free survival in a cohort of 88 patients [77]. Along
with this, immunohistochemical tissue staining for PDIP46
in the Human Protein Atlas (http://www.proteinatlas.org)
[78] shows a pattern of lowered expression of POLDIP3 in
20 of the most common cancers. The COSMIC (catalogue
of somatic mutations in cancer,) database (http://cancer.
sanger.ac.uk/cosmic) [79] also contains data on mutation
spectra and altered copy number and expression of
POLDIP3 in cancer tissues. These findings are consistent
with a role of PDIP46 in the maintenance of genomic
stability.
In summary, our current studies have provided the
first analysis of the functional effects of PDIP46 on Pol δ
activity. These add to the complexity of PDIP46 functions
in relation to those associated with SKAR, but also
provide insights and avenues for further dissection of their
respective contributions to cellular functions in growth
control and genomic stability. Our studies also point to
caution in interpretation of the effects of PDIP46/SKAR
depletion in cellular studies, because of its bifunctional
nature. Thus, future studies in which expression of the
two functional domains of PDIP46 in a PDIP46 null cell
background are required. Overall, our studies add to the
evidence that PDIP46/SKAR is a protein of significant
interest in relation to genomic stability and as a potential
marker for tumor progression.

PDIP46 as a multifunctional protein and its
potential impact on genomic instability
Our studies have now defined PDIP46 as having
the potential at the biochemical level to participate in
DNA replication. At the same time, PDIP46 has been
studied as the SKAR protein whose functions reside in
the RRM domain that contains the interaction site for
S6K1. SKAR functions provide a linkage to the mTOR
pathway for control of cell growth via its recruitment with
S6K1 to the exon junction complex where it plays roles
in mRNA processing and translational control [29, 30].
SKAR has shown to play a key role in the IFN stimulated
expression of genes that are critical for the antileukemic
and antineoplastic responses in the use of IFNs in cancer
immunotherapy [72]. This involves interferon (IFN)-α
induced phosphorylation of SKAR by p90 ribosomal
protein S6 kinase (RSK1).
The roles of the C-terminal region may be even
more complex, since PDIP46 also interacts with ERH
(enhancer of rudimentary homolog) [73], a connection
that provides linkages to cell cycle control and DNA
replication. ERH is a transcriptional regulator that is
required for the splicing of the mitotic motor protein
CENP-E, and affects the expression of multiple cell cycle
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

Western blotting, Co-immunoprecipitation and
ChIP assays

Expression and purification of protein reagents

Western blotting for Pol δ subunits was performed
using antibodies against p125, p50, p68 and p12 [12, 14,
19]. PCNA antibodies used were a monoclonal antibody
[83,84] or PC10 (Santa Cruz Biotechnology). A rabbit
polyclonal antibody against PDIP46 was generated by
Proteintech Group.
A549 human lung adenocarcinoma, HEK 293 and
HeLa cells were obtained from ATCC and maintained
according to protocols from the supplier [12, 14, 19]. The
cells were lysed by sonication and centrifuged at 14,000
rpm for 10 min. Primary antibodies were added overnight
followed by addition of A/G agarose beads (Santa Cruz
Biotechnology) for 1 hour, at 4° C. The beads were spun
down and washed 8 times with RIPA buffer followed by
suspension in 2X SDS loading buffer. The bound proteins
were analyzed using SDS-PAGE and Western blotted for
the test proteins.
ChIP analysis was performed essentially as
previously described [14]. A549 cells were grown on 15
cm2 plates and cross-linked by addition of formaldehyde
(1%) for 10 minutes at room temperature. The crosslinking reaction was terminated by the addition of glycine
to a final concentration of 0.25 M. Cells were harvested
and ChIP assays using anti-p125 or control IgG were
performed using a ChIP-IT Express Enzymatic Kit (Active
Motif, Carlsbard, CA). Immunoprecipitated proteins were
analyzed by SDS-PAGE and western blotted for PDIP46
and p125. Antibodies to Mcm2 and Ctf4 used as positive
controls were obtained from Santa Cruz Biotechnology.

For the pull-down assays, wild type GST-PDIP46,
deletion mutants of GST-PDIP46, GST-p50 and truncated
GST-p50 fragments were generated by PCR; the PCR
generated fragments were digested with restriction
endonucleases and subcloned in pGEX-5X-3 (Amersham
Pharmacia Biotech,). His-tagged p50 was expressed in the
PET33b vector [80]. His-tagged PDIP46 was expressed
in the pTacTac vector with eight histidine residues added
at its N-terminus. GST fusion or his-tagged proteins were
expressed in E. coli BL21DE3 (pLysS), and purified
by using either glutathione beads (GE Healthcare Life
Sciences) or Ni-NTA agarose (Qiagen).
Recombinant human Pol δ4 and Pol δ3 were
expressed in insect cells and purified to near homogeneity
[47]. PDIP46 was first expressed as the his-tagged-SumoPDIP46 fusion protein using the pET Sumo vector (Life
Technologies) and purified on Ni-NTA columns. The hisSumo tags were removed by Sumo protease, and PDIP46
was further purified to near homogeneity by FPLC on
Mono S 10/100 ion exchange columns (GE Healthcare
Life Sciences). The PDIP46-∆RRM (deletion of residues
280-351) and PDIP46-5A mutants were generated
using QuikChange mutagenesis kits (Stratagene).
Concentrations of Pol δ (p125 subunit content), PDIP46
and its mutants were determined by SDS-PAGE with a
range of concentrations of catalase as protein standard
(Fig. S6, Supplementary Data). Human PCNA was
expressed in E. coli and purified as previously described
[81, 82].

Native gel electrophoresis

GST pull-down assays

HEK 293 cells from five 75-cm2 flasks were
harvested and extracts were prepared as described
previously [9, 28]. Samples (150 µl, 10 mg/ml protein)
were run on 5–15% gradient polyacrylamide gels with
a 3.5% stacking gel at 4° C in the absence of SDS.
Thyroglobulin (Mr 669,000), ferritin (Mr 440,000) and
catalase (Mr 232,000) were used as markers. Gels were run
until the migration of the protein standards was limited by
pore size (18 h), as established by trial experiments. The
proteins were transferred to nitrocellulose membranes and
immunoblotted for p125 and PDIP46.

GST-PDIP46, GST-PDIP46 truncated deletion
mutants and GST (control) were incubated with the same
amounts of PCNA (or other test proteins) in 600 μl binding
buffer (50 mM Tris-HCl, pH 7.8, 1 mM EDTA, 150 mM
NaCl, 0.1% NP-40 and 0.2 mM phenylmethylsulfonyl
fluoride). The reaction mixtures were incubated by gentle
rocking for one hour at 4˚C. Packed glutathione beads
were added (15 μl) and the suspension further rotated for
another hour at the same temperature. The beads were
spun down at 2,500 rpm for 5 minutes and washed 8 times
with the binding buffer followed by suspension in 1 X
SDS loading buffer. The bound proteins were analyzed
by SDS-PAGE and Western blotted with antibody against
PCNA or other test proteins. Similar protocols were used
for other pull-down assays.
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Assay for processive synthesis by Pol δ on singly
primed M13 ssDNA
Assays using singly primed M13 DNA as the
template were performed as previously described [12, 47].
Single stranded M13mp18 DNA (7250 bp, New England
Biolabs, MA) was primed with a 20-mer oligonucleotide
6309
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(5’-CTAGAGGATCCCCGGGTACC-3’) complementary
to nucleotides 6262–6243 of the M13 genome. The
standard reaction contained 40 mM Tris-HCl, pH 7.8, 1
mM dithiothreitol, 0.2 mg/ml BSA, 10 mM MgCl2, 0.5
mM ATP, 50mM NaCl, 250 μM each of dTTP, dCTP, and
dGTP, and 25 μM cold dATP with 3 μCi of [α-32P]-dATP,
2.5 nM primed M13 template, 6 nM human RFC, 6 nM
PCNA, 250 nM RPA in a final volume of 16 µl. PCNA
was first loaded onto the primed M13 DNA in the presence
of RFC, RPA, ATP and Mg2+. Pol δ concentrations ranged
from 5 nM to 60 nM as indicated in the figure legends.
Pol δ was pre-incubated with PDIP46 on ice for 5 min
prior to reaction. The reaction was started by the addition
of Pol δ, or Pol δ with PDIP46. The reaction mixtures
were incubated at 37 °C for the indicated times and were
terminated by the addition of 120 mM EDTA. The reaction
products were run on 1.2% alkaline agarose gels at 70
V for 1.5 h. The gels were dried and visualized using a
Molecular Dynamics Storm PhosphorImager system
and quantified with ImageQuant software (Amersham
Bioscience, NJ).

loading buffer contained 50 mM EDTA, 95% formamide,
0.01% bromophenol blue, 0.01% xylene cyanol. Reaction
products were subjected to electrophoresis on sequencing
gels (16–20% acrylamide/bisacrylamide 19:1 (BioRad), 7.4 M urea, 1 mM EDTA, 90 mM Tris–HCl and
90 mM boric acid). Reaction products were visualized
by phosphorimaging with a Molecular Dynamics Storm
Phosphorimaging system and quantified with ImageQuant
software (Amersham Biosciences).
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Editorial note

Assays for primer extension and strand
displacement synthesis using oligonucleotide
substrates

This paper has been accepted based in part on peerreview conducted by another journal and the authors’
response and revisions as well as expedited peer-review
in Oncotarget.

The primer/templates used for primer extension and
strand displacement were as previously described [27].
The template for primer extension consisted of a 70mer:
5’-biotin-CCT ATC TGA GCA CTA TCA TCG GTC GCA
TCG TTG GCT GAA ATC GTG CTG TAG TGG CTG
AAT CCC AAC CAA C-3’-biotin, where the ends were
tagged with biotin. The 34mer primer sequence was 5’GTT GGT TGG GAT TCA GCC ACT ACA GCA CGA
TTT C-3’. This primer was 5’ end-labeled with 32P and
annealed to the template [27]. For strand displacement
assays, a 31mer blocking oligonucleotide, 5’-ACG ATG
CGA CCG ATG ATA GTG CTC AGA TAG G-3’ was also
annealed downstream from the primer. Streptavidin was
used to block the template ends and PCNA was loaded
with RFC [27]. The hairpin substrate consisted of a 64mer
template, 5’-GCG ATG CGA CCG ATG ACC CCC CCC
TCA TCG GTC GCA TCG CTG GCT GTC AAG GTG
CTG TAG TGG C-3’, where the underlined sequences are
complementary and formed the hairpin. This was annealed
to a 5’ -32P-end labeled 19mer primer, 5’-GCC ACT ACA
GCA CCT TGA C-3’.
Pol δ and PDIP46 were pre-incubated on ice for 5
min before they were added to the reaction mixture. The
reaction contained 50 nM or 100 nM of DNA, Pol δ and
PDIP46 as indicated, 50 mM Tris-HCl pH 7.5, 50 mM
NaCl, 2 mM dithiothreitol, 0.1mg/ml BSA, 5 mM MgCl2,
and 0.15 mM dNTP. MgCl2 and dNTPs were added to
the mixture to start the reactions, and equal volumes of
gel loading buffer were added to stop the reactions. The
www.impactjournals.com/oncotarget
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